Q-omics provides the consensus-scored LDLRAD4 profile across patient tissues and cancer cell-line models. LDLRAD4 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LDLRAD4 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, LDLRAD4 RNA expression shows 19,121 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where LDLRAD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LDLRAD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LDLRAD4 survival associations across molecular data types. LDLRAD4 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LDLRAD4 RNA expression–survival associations across cancer types. High LDLRAD4 expression shows unfavorable associations in MESO and UVM, but favorable associations in KIRC, HNSC, LUAD and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LDLRAD4 RNA expression.
This table summarizes LDLRAD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LDLRAD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LDLRAD4 shows lower tumor expression in KICH, BLCA, KIRP, LUAD and LUSC and higher tumor expression in KIRC. The KICH box plot shows higher LDLRAD4 RNA expression in normal versus tumor tissue (log2 FC = −1.527, t-test p < 0.001).
This table shows molecular features associated with LDLRAD4 in patient tissues and cancer cell lines. In patient samples, LDLRAD4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LDLRAD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and STOMACH.
